Cargando…

Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis

(1) Background: With the aging of the population and polypharmacy encountered in the elderly, drug-induced steatosis (DIS) has become frequent cause of non-alcoholic steatosis (NAS). Indeed, NAS and DIS may co-exist, making the ability to distinguish between the entities ever more important. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omanovic Kolaric, Tea, Kizivat, Tomislav, Mihaljevic, Vjera, Zjalic, Milorad, Bilic-Curcic, Ines, Kuna, Lucija, Smolic, Robert, Vcev, Aleksandar, Wu, George Y., Smolic, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406665/ https://www.ncbi.nlm.nih.gov/pubmed/36005135 http://dx.doi.org/10.3390/cimb44080239

Ejemplares similares

Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy
por: Ninčević, Vjera, et al.
Publicado: (2022)

Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy
por: Mihaljević, Vjera, et al.
Publicado: (2022)

Pretreatment of Garlic Oil Extracts Hampers Epithelial Damage in Cell Culture Model of Peptic Ulcer Disease
por: Kuna, Lucija, et al.
Publicado: (2022)

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
por: Ninčević, Vjera, et al.
Publicado: (2019)

Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update
por: Kolaric, Tea Omanovic, et al.
Publicado: (2023)

Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update
por: Duspara, Kristina, et al.
Publicado: (2021)

Management of Glycemia during Acute Aerobic and Resistance Training in Patients with Diabetes Type 1: A Croatian Pilot Study
por: Ivandic, Marul, et al.
Publicado: (2023)

Antioxidant Pre-Treatment Reduces the Toxic Effects of Oxalate on Renal Epithelial Cells in a Cell Culture Model of Urolithiasis
por: Kizivat, Tomislav, et al.
Publicado: (2017)

Hepatitis C Virus, Insulin Resistance, and Steatosis
por: Kralj, Dominik, et al.
Publicado: (2016)

Mechanisms of Hepatic Cholestatic Drug Injury
por: Kolarić, Tea Omanović, et al.
Publicado: (2019)

Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients’ Population
por: Bojanic, Kristina, et al.
Publicado: (2020)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
por: Petrovic, Ana, et al.
Publicado: (2023)

IMPACT OF GRAVES’ DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY – PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE
por: Mudri, Dunja, et al.
Publicado: (2022)

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
por: Bojanić, Kristina, et al.
Publicado: (2018)

Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
por: Bilic Curcic, Ines, et al.
Publicado: (2021)

Drug-induced Fatty Liver Disease: Pathogenesis and Treatment
por: Kolaric, Tea Omanovic, et al.
Publicado: (2021)

Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update
por: Ćurčić, Ines Bilić, et al.
Publicado: (2022)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
por: Kishta, Sara, et al.
Publicado: (2020)

Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications
por: Kizivat, Tomislav, et al.
Publicado: (2020)

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
por: Vukadin, Sonja, et al.
Publicado: (2021)

Hyperthyroidism and Wnt Signaling Pathway: Influence on Bone Remodeling
por: Mudri, Dunja, et al.
Publicado: (2023)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Primary Care Provider Counseling Practices about Adverse Drug Reactions and Interactions in Croatia
por: Raguz Lucic, Nikola, et al.
Publicado: (2018)

Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?
por: Curcic, Ines Bilic, et al.
Publicado: (2019)

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives
por: Kuna, Lucija, et al.
Publicado: (2018)

The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
por: Roguljić, Hrvoje, et al.
Publicado: (2022)

Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options
por: Kuna, Lucija, et al.
Publicado: (2019)

Molecular Mechanisms Responsible for Diabetogenic Effects of COVID-19 Infection—Induction of Autoimmune Dysregulation and Metabolic Disturbances
por: Grubišić, Barbara, et al.
Publicado: (2023)

Wnt Inhibitors and Bone Mineral Density in Patients with Graves’ Disease Treated with Antithyroid Drugs: A Preliminary Prospective Study
por: Mudri, Dunja, et al.
Publicado: (2022)

Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
por: Khaznadar, Farah, et al.
Publicado: (2023)

LIFESTYLE RISK FACTORS AND BONE MASS IN RECURRENT STONE-FORMING PATIENTS: A CROSS-SECTIONAL STUDY IN 144 SUBJECTS
por: Marić, Ivana, et al.
Publicado: (2019)

The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis
por: Moon, Young-Ah
Publicado: (2017)

HCV Extrahepatic Manifestations
por: Kuna, Lucija, et al.
Publicado: (2019)

GP73 regulates Hepatic Steatosis by enhancing SCAP-SREBPs interaction
por: Yang, Xiaoli, et al.
Publicado: (2017)

FRI063 Effectiveness Of Liraglutide In Treating Obesity And Improving Hepatic Steatosis
por: Alfadda, Assim Abdulaziz, et al.
Publicado: (2023)

Glycosylation Alterations in Cancer Cells, Prognostic Value of Glycan Biomarkers and Their Potential as Novel Therapeutic Targets in Breast Cancer
por: Peric, Luka, et al.
Publicado: (2022)

Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway
por: Fang, Yunyun, et al.
Publicado: (2020)

Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
por: Schönberger, Ema, et al.
Publicado: (2023)

Impact of Breast Density Awareness on Knowledge about Breast Cancer Risk Factors and the Self-Perceived Risk of Breast Cancer
por: Bojanic, Kristina, et al.
Publicado: (2020)

Inhibition of LXRα/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule
por: Wang, Miao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3t4ht8lnufbeduqqil8kurn4qr